^
Association details:
| Biomarker: | ALK L1152R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Excerpt:
The EML4-ALK L1152R cells were significantly more resistant than the parental cells to both crizotinib (Figure 1B) and ALK inhibitor TAE684.
DOI:
10.1158/0008-5472.CAN-11-1340
Trial ID:
